DiMarchis quote as follows: Many diseases share the same root causes, which is inhibition of AMPK activity leading to disruption of many metabolic pathways. GLP-1 drugs activate AMPK primarily through reducing calorie intake
Personalization remains essential
Researchers found two ways to fix this: using higher doses of medication or combining lower doses with special helper molecules for some mutations
Even though the shortage resolved in late 2024, Alka Menon, a sociologist at Yale University, said compounded GLP-1s continue to proliferate, with little oversight over the drugs themselves and the popular pathways for accessing them, like telehealth companies
16 These impaired DNA modifications can accelerate aging and cause neurodegenerative, carcinogenesis, autoimmune, cardiovascular, and other diseases